Canopy Growth: Turnaround Is Real, But At $1 Billion It Needs To Prove It Lasts

Canopy Growth reported fiscal Q1 2027 results that read like the best quarter the company has posted in two years — and also the most complicated one to rate. Revenue grew 13% to $81.2 million (CAD), gross margin expanded to 27%, the adjusted EBITDA loss narrowed 59%, and the net loss shrank 68% versus the prior year. The EPS beat of -$0.02 versus a -$0.04 estimate is a 50% improvement on what the street expected.

The stock, which closed near $1.92 and sits around a $976 million market cap, is in the middle of its 52-week range. The market has not yet decided whether this is inflection or a temporary blip. Neither has the math.

Here is the breakdown. The rating is Hold: the operating turnaround is genuine, but the valuation is asking for proof of persistence before it deserves a Buy.

What changed in Q1 FY2027

All four business segments grew. That is the headline improvement, because quarters where everything expands are rare for a company that has been pruning, restructuring, and fighting for share for years.

Canada adult-use cannabis brought in $29.7 million, up 10%. Canada medical cannabis rose 22% to $25.8 million, driven by growth in insured patients. International cannabis revenue hit $9.6 million, up 10%, with particular strength in Poland. Storz & Bickel, the vaporizer business, grew 6% to $16.1 million. No segment dragged. That broad-based growth matters more than any single segment number because it shows the cost-cutting and integration work is not cannibalizing one division to feed another.

Margins improved in a way worth examining closely. Reported gross margin rose to 27% from 25% last year. Adjusted gross margin — which excludes acquisition-related charges — reached 31%. But that 31% figure includes $2.6 million in inventory step-up charges from the MTL Cannabis acquisition. Step-up charges are one-time accounting write-ups on acquired inventory that inflate current cost of goods sold. Stripping them out makes the margin look better, but the underlying cannabis segment adjusted gross margin was 26%, only one point better than last year. The real margin story is in Storz & Bickel, where gross margin jumped to 48% from 29% thanks to cost rationalization and recovery of certain U.S. tariffs. That vaporizer business has become the highest-margin part of the company.

The adjusted EBITDA loss — earnings before interest, taxes, depreciation, and amortization, a rough proxy for cash operating earnings — narrowed to $3.2 million from $7.9 million a year ago. On an $81.2 million revenue base, being $3.2 million from break-even is not profitability, but it is the closest Canopy Growth has been in a long time. The net loss compression from $44.9 million to $14.6 million is even more dramatic, though the wider gap between EBITDA and net income reflects interest, depreciation, and non-cash charges that do not show up in the EBITDA line.

The problem with the free cash flow

Free cash flow got worse, not better. The company burned $25.7 million in free cash flow versus $11.6 million in the prior-year quarter. Management attributed this to timing of working capital changes. That is plausible — inventory build and receivables swings can create quarter-to-quarter noise. But burning more than twice as much cash in a quarter where revenue grew and margins expanded is not the pattern you want to see at a company claiming inflection.

Cash on the balance sheet stands at $336.6 million against $240.2 million in total debt. Net cash is roughly $96 million. At a $25.7 million quarterly burn rate, the runway is about 13 quarters, or three years, if things stay exactly where they are. If the company sustains its cost-cutting trajectory and EBITDA moves toward zero, that runway extends. If working capital keeps pulling in the opposite direction, it shortens.

Selling expenses came in at $40.2 million, up 6% year-over-year, with the MTL Cannabis integration adding costs that were only partially offset by headcount reductions. SG&A at $40.2 million on $81.2 million of revenue is a 49% ratio. The company has to get that below revenue before free cash flow turns positive. That is the operational target.

The MTL Cannabis integration

The MTL Cannabis acquisition is the strategic centerpiece of the current management team under CEO Luc Mongeau. MTL contributes genetic material and production capacity, which Canopy Growth is using to relaunch its Tweed brand in the German medical market and expand flower supply in Canada. Management says further financial improvements are expected in the second half of fiscal 2027 as integration completes.

That is a claim worth testing. The Q1 results show MTL has already added to revenue in both Canadian segments, which is encouraging. The inventory step-up charges are a reminder that acquisition accounting is still flowing through the income statement. The real test is whether MTL synergies reduce the SG&A-to-revenue ratio over the next two quarters, not just add top-line volume.

Valuation: the number that matters

Canopy Growth's market cap of roughly $976 million implies an enterprise value of about $780 million after netting cash against debt. Annualized against the $81.2 million quarterly revenue, that is roughly 9.6 times trailing sales. On a more realistic trailing-twelve-month basis — total revenue was about $193 million over the past year — the P/S multiple is closer to 5.1.

Compare that to Tilray, the nearest Canadian peer, which generates roughly $210 million per quarter — more than double Canopy Growth's run rate — and at least has reached profitability. A company that is still losing money, burning free cash flow, and generating less than $325 million in annual revenue should not command a 5-plus-times sales multiple unless the growth trajectory and margin path are convincingly steep. The Q1 results are moving in the right direction. They are not yet steep enough.

The per-share economics are also a reminder of how much equity has been issued over the years. With 423 million common shares and 26 million exchangeable shares outstanding, each share represents a small slice of a business that has yet to turn a profit. Dilution risk is lower now than it was two years ago — the company has pivoted from equity issuances to debt financing and asset sales — but the share count is still large.

Catalysts and what to watch

The next earnings report is scheduled for November 6, 2026. That quarter will be the first full test of whether Q1 was a turning point or an anomaly. What to monitor:

• Free cash flow: If the $25.7 million burn rate repeats or worsens, the margin story loses credibility.
• SG&A trajectory: The $40.2 million selling expense needs to come down as a percentage of revenue. MTL integration costs should taper.
• Canada medical growth: The 22% segment gain was partially offset by reduced Veterans Affairs Canada reimbursement rates. If government reimbursement pressure continues, medical growth could slow.
• Tweed in Germany: The relaunch is the most visible international growth lever beyond Poland. Early volume data will appear in the Q2 print.
• Updated guidance: Management did not provide fresh full-year numerical guidance in the Q1 release. A guidance raise in November would be the signal that changes the rating.

The rating

Canopy Growth is not in danger. It has $336 million in cash, a narrowing loss profile, a shrinking debt load, and a business where all segments grew for the first time in a long stretch. The cost-cutting discipline under Mongeau is real, not rhetorical. Storz & Bickel has become a profitable high-margin asset. The MTL integration is underway rather than aspirational.

But at a $1 billion market cap, Canopy Growth is priced asif the turnaround is already complete. It is not. The company is still losing money, burning free cash flow, and operating on a revenue base that is small enough that a single rough quarter sets the narrative back months. A 5-plus-times sales multiple on an unprofitable cannabis operator is not cheap. It is fair only if the trajectory holds.

Hold. The path to a Buy requires one of two things: a material guidance raise in November that projects the company toward annual profitability, or a stock selloff that brings the enterprise value below 7 times trailing sales. Until one of those happens, the risk/reward at $1.92 per share does not justify a Buy.

What would reverse the call to the downside? A repeat of the working capital cash burn, another quarter of flat or declining revenue in Canada, or a failure to reduce the SG&A ratio below its current 49% level. Those would confirm that the Q1 improvement was a one-off rather than a trend.